Roche: Rozlytrek wins additional indication in Japan

(CercleFinance.com) - Roche's Chugai has obtained approval from Japanese regulators for an additional indication of its anticancer drug Rozlytrek for the treatment of an advanced form of lung cancer.


The tyrosine kinase inhibitor has been approved for the treatment of ROS1 fusion-positive, unresectable, advanced or metastatic non-small cell lung cancer by Japan's Ministry of Health, Labour and Welfare, the drugmaker said.

Rozlytrek was launched last June as Chugai's first product in advanced personalized healthcare for the treatment of patients with solid tumors.

Copyright (c) 2020 CercleFinance.com. All rights reserved.